Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cellectis SA

CLLS
Current price
1.55 USD -0.02 USD (-1.27%)
Last closed 1.46 USD
ISIN US15117K1034
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 146 423 408 USD
Yield for 12 month -47.81 %
1Y
3Y
5Y
10Y
15Y
CLLS
21.11.2021 - 28.11.2021

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Address: 8 rue de la Croix Jarry, Paris, France, 75013

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.60 USD

P/E ratio

Dividend Yield

Current Year

+41 506 000 USD

Last Year

+755 000 USD

Current Quarter

+10 655 000 USD

Last Quarter

+12 717 000 USD

Current Year

+21 631 000 USD

Last Year

+18 000 USD

Current Quarter

+8 640 000 USD

Last Quarter

+6 887 000 USD

Key Figures CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -48 252 000 USD
Operating Margin TTM -70.43 %
Price to Earnings
Return On Assets TTM -10.37 %
PEG Ratio
Return On Equity TTM -34.08 %
Wall Street Target Price 5.60 USD
Revenue TTM 49 217 000 USD
Book Value 1.82 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 662.10 %
Dividend Yield
Gross Profit TTM 49 217 000 USD
Earnings per share -0.67 USD
Diluted Eps TTM -0.67 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -74.69 %

Dividend Analytics CLLS

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio TTM
Last Split Date

Stock Valuation CLLS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.78
Price Sales TTM 2.98
Enterprise Value EBITDA -3.90
Price Book MRQ 1.29

Financials CLLS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CLLS

For 52 weeks

1.10 USD 3.00 USD
50 Day MA 1.38 USD
Shares Short Prior Month 340 330
200 Day MA 1.76 USD
Short Ratio 3.25
Shares Short 317 825
Short Percent 0.39 %